VasoCare. Vasogen.
Vasogen is developing VasoCare, an immune modulation therapy, as a potential treatment for peripheral vascular disease (PVD) and atherosclerosis [308287], [388266]. In December 1998, VasoCare was in late phase II trials in the UK for PVD [308287], and by October 2000, phase I/II trials were underway in the US, Canada and Europe [388254]. By March 2001, Vasogen was planning to launch a US multicenter trial in PVD in support of regulatory approval [402091]. In June 2001, the USPTO issued a patent entitled 'Method for Preventing and Reversing Atherosclerosis', covering the use of VasoCare in the prevention and reduction of atherosclerosis [411783].
Visioli
F
F
University of Milan, Department of Pharmacological Sciences, Via Balzaretti 9, 20133, Milan, Italy. francesco.visioli@unimi.it
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D000276:Adjuvants, Immunologic